Bioterror “Strategic Investor” Initiative Must Be Resolved As House, Senate Pass Dueling Bills

House- and Senate-passed bills reauthorizing the 2006 Pandemic and All-Hazards Preparedness Act are similar in many respects in their efforts to accelerate medical countermeasure development. However, the House bill lacks a Senate provision that would allow HHS to contract with a non-profit entity to invest in companies developing countermeasures.

Establishment of a public-private partnership that would invest in companies developing medical countermeasures is one of the key differences to be reconciled when House and Senate bills reauthorizing the Pandemic and All-Hazards Preparedness Act head to a conference committee.

The measures are similar in that they would reauthorize funding for activities under the 2006 PAHPA law through 2014, expand...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

Crosstalk On Drug Pricing: Conflicts In Trump Team Rhetoric And Policy

 

The Trump Administration’s rhetoric and policy approaches illustrate the confusion that often arises between efforts to cut drug prices and cutting spending.

Price Inflation Rebates: Biden Policies Add Teeth To Trump’s Pharma Tariff Threat

 
• By 

Companies with significant exposure to Medicare and Medicaid have fewer options for passing along higher costs to consumers because of price controls in the programs.

US FDA Acting Drug Center Chief Corrigan-Curay Retiring, Senior Staff Remake Continues

 

The news coincides with rumors that Commissioner Martin Makary soon will name a new Center for Drug Evaluation and Research director.

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.

More from North America

US FDA’s Elsa AI Platform Is Not Guiding Regulatory Decisions, Official Says

 
• By 

Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.

Branch Chief Vijay Kumar Named Acting Head Of US FDA’s Cell, Gene Therapy Office

 

Kumar takes over as acting director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products days after director Nicole Verdun was ousted.

Recent And Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.